Comparative Pharmacology
Head-to-head clinical analysis: CARBOPLATIN versus EMCYT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBOPLATIN versus EMCYT.
CARBOPLATIN vs EMCYT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carboplatin forms platinum-DNA adducts, causing intrastrand crosslinks and G2/M cell cycle arrest, leading to apoptosis.
Estramustine is a combination of estradiol and nitrogen mustard. The estradiol moiety targets the drug to cells expressing estrogen receptors, while the nitrogen mustard alkylates DNA, inhibiting cell division primarily in prostate cancer cells.
IV infusion over 15-60 minutes, target AUC 4-6 using Calvert formula (dose = target AUC × (GFR + 25)). Adults: typical initial dose 400 mg/m² every 4 weeks or AUC 5-6 every 3-4 weeks.
Estramustine phosphate sodium: 14 mg/kg/day orally in 3-4 divided doses, typically 140 mg four times daily. Administer on an empty stomach (1 hour before or 2 hours after meals).
None Documented
None Documented
Clinical Note
moderateCarboplatin + Digoxin
"Carboplatin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCarboplatin + Digitoxin
"Carboplatin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCarboplatin + Deslanoside
"Carboplatin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCarboplatin + Acetyldigitoxin
"Carboplatin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 2.6-5.9 hours in adults with normal renal function. In patients with creatinine clearance <60 mL/min, half-life is prolonged (up to 17-26 hours). Clinically, dosing adjustments are required based on Calvert formula using glomerular filtration rate.
Terminal half-life of estramustine phosphate: ~20 hours; estromustine: ~14 hours; clinical context: supports daily dosing with accumulation over 5-7 days
Renal: ~65% of platinum excreted in urine within 24 hours, primarily as unchanged carboplatin; ~32% as metabolites. Biliary/fecal excretion is minimal (<6%).
Renal: primarily as estramustine phosphate, estromustine, and estradiol; <1% as unchanged drug; fecal: ~15%
Category D/X
Category C
Alkylating Agent
Alkylating Agent